VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (AMD), today announced upcoming scientific and corporate presentations on its implantable telescope technology. VisionCare's investigational telescope implant is the first medical device to be recommended for FDA approval by the FDA Ophthalmic Devices Advisory Panel for End-Stage AMD, a leading cause of untreatable blindness in the U.S.
Three podium presentations are scheduled as follows: American Academy of Ophthalmology (AAO) Annual Meeting October 23 - 27, 2009 - Moscone Center, San Francisco. - Friday, October 23 Session: AAO Retina 2009 Subspecialty Day, Late Breaking Developments Location: Moscone Center South, Esplanade Ballroom 3:28 PM Long-term Data on the Implantable Telescope Technology Jeffrey S. Heier, MD, Vitreoretinal Specialist, Ophthalmic Consultants of Boston, Boston, MA. - Monday, October 26 Session: AAO Joint Meeting, Symposium 25 Location: Moscone Center South, Esplanade Ballroom 5:14 PM Implantable Miniaturized Telescope Mark R. Wilkins, MD, Cornea/Cataract Specialist, Moorfields Eye Hospital, London. Ophthalmology Innovation Summit (OIS) October 22, 2009 - The Palace Hotel, San Francisco. - 8:50 AM VisionCare Ophthalmic Technologies Allen W. Hill, President and CEO
At the AAO annual meeting, VisionCare is in Booth #5437 located in the West Hall of the Moscone Convention Center.
AI-powered MRI predicts outcomes in prostate cancer